资源描述
PPT文章主标题位置,PPT文章主标题位置,2015-ASCO软组织肉瘤研究进展,内容概要,胃肠道间质瘤（GIST）-GIST辅助治疗进展-Abstract 10505-GIST晚期治疗进展-Abstract 10506软组织肉瘤研究进展-Abstract 10500-Abstract 10502-Abstract 10503,胃肠道间质瘤（GIST）,Abstract10505 - GIST辅助治疗,SSGXVIII/AIO研究-,意向人群 5年RFS,Presented By Heikki Joensuu at 2015 ASCO Annual Meeting,有效人群5年RFS,意向人群 OS,Presented By Heikki Joensuu at 2015 ASCO Annual Meeting,有效人群OS,Safety during adjuvant imatinib,Presented By Heikki Joensuu at 2015 ASCO Annual Meeting,IM 治疗安全性,Presented By Heikki Joensuu at 2015 ASCO Annual Meeting,IM治疗后心脏事件及继发性肿瘤发生情况,SSGXVIII/AIO GIST辅助治疗结论,3年IM辅助治疗仍是标准接受3年辅助治疗-5年RFS为70%，1年辅助治疗-5年RFS为50%.GIST接受IM治疗耐受性较好高危GIST患者的5年生存率达到90%成为现实高危GIST患者是否需要进一步延长辅助治疗时间（5年 VS 3年）需要进一步临床试验验证.,Abstract10505 SSGXVIII/AIO结论,Presented By Robert Maki at 2015 ASCO Annual Meeting,Abstract10506 - GIST晚期治疗进展,Study design,Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,研究设计,（入组患者至少已经接受过两种药物）,Objectives and endpoints,Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,研究终点,Progression-Free Survival(investigator-assessed progression),Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,PFS研究结果,4个月PFS率,Overall Survival,Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,OS 研究结果,Exploratory objectives,Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,分子分型对pazopanib的疗效分析,Exploratory objectives,Presented By Jean-Yves Blay at 2015 ASCO Annual Meeting,血浆Pazopanib浓度对PFS的影响,Presented By Robert Maki at 2015 ASCO Annual Meeting,手术对PFS的影响,Abstract10505： PAZOGIST结论,IM及SU发生耐药后， 接受Pazopanib治疗使PFS获益Pazopanib组4monthsPFS为45.2%而安慰剂组4monthsPFS为17.6%OS并未获益探索性分析：血浆浓度pzaopanib有影响 手术患者接受pazopanib治疗未获益 未手术的HR为0.38对于晚期GIST，Pazopanib值得进一步研究,软组织肉瘤研究进展,Abstract 10500：GeDDiS 研究,研究设计：阿霉素 VS 健泽+多西,研究结果:PFS,研究结果:OS,Subgroup analyses,Presented By Beatrice Seddon at 2015 ASCO Annual Meeting,亚组分析,（平滑肌肉瘤）,（非平滑肌肉瘤）,Subgroup analyses,Presented By Beatrice Seddon at 2015 ASCO Annual Meeting,亚组分析,（子宫平滑肌肉瘤）,（非子宫平滑肌肉瘤）,Subgroup analyses,Presented By Beatrice Seddon at 2015 ASCO Annual Meeting,（女性）,（男性）,Grade 3 or 4adverse events,Presented By Beatrice Seddon at 2015 ASCO Annual Meeting,3-4级毒性,GeDDiS 研究结论,与dox相比：GEM联合DOC并未使PFS获益；并且HR分析显示接受dox治疗能够降低疾病进展风险.两组之间OS无显著差异；亚组分析：平滑肌肉瘤和非平滑肌肉瘤两组之间PFS均无差异；子宫平滑肌肉瘤与非子宫平滑肌肉瘤两组之间PFS也无差异；有一些证据表明男性患者接受doxcrubicin能够降低疾病进展风险；GEM联合DOC未能获益可能的原因：中途退出研究的患者比例较大 剂量强度不够及治疗周期延误,Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI),Presented By Patrick Schoffski at 2015 ASCO Annual Meeting,Abstract 10502: Eribulin(艾日布林) VS Dacarbazine（达卡巴嗪）,Study design and objectives,Presented By Patrick Schoffski at 2015 ASCO Annual Meeting,研究设计和研究终点,Primary endpoint: OS,Presented By Patrick Schoffski at 2015 ASCO Annual Meeting,研究结果: os,Secondary endpoint: PFS,Presented By Patrick Schoffski at 2015 ASCO Annual Meeting,次要研究终点：PFS,Summary of AEs, based on CTCAE v4.021,Presented By Patrick Schoffski at 2015 ASCO Annual Meeting,毒性,What about cost effectiveness?Cost per cycle: eribulin $5,511, dacarbazine $78Data supplied by ASCO,Presented By Ian Judson at 2015 ASCO Annual Meeting,经济效价,Abstract 10502总结,与达卡巴嗪相比较，晚期患者接受艾日布林治疗使OS获益（13.5m VS 11.5m, HR0.768,P=0.0169) 两类药物在常见毒副反应发生率方面总体相似 考虑到软组织肉瘤发病率低及治疗棘手，该研究结果具有 一定的临床意义.,Abstract10503 trabectedin (曲贝替定）VS Dacarbazine,中期OS分析,血小板减少和咳嗽低于达卡巴嗪，其他都高于,Abstract10503 结论,接受Trabectedin（曲贝替定）治疗使PFS获益（mPFS:4.2m VS 1.5m, P0.0001） 3m及6m的PFS率与既往报道相符合Trabectedin:分别为56%和37%Dacarbazine:分别为34%和14% Trabectedin能够使疾病控制时间延长 尽管中期分析OS未获益，考虑其毒性可耐受，接受Trabectedin治疗6cycles以上患者比例达到34%（Dacarbazine为17%）对于晚期脂肪肉瘤和平滑肌肉瘤患者Trabectedin是一种重要的治疗方法.,内容小结,Abstract10505 - -SSGXVIII/AIO研究GIST辅助治疗进展：3年IM辅助治疗仍是标准Abstract10506 -PAZOGIST研究晚期GIST患者IM及SU耐药后接受Pazopanib 治疗使PFS获益Abstract 10500 - GeDDiS 研究dox相比：GEM联合DOC并未使PFS获益，OS相似 Abstract 10502- EribulinVS Dacarbazine与达卡巴嗪相比较，晚期患者接受艾日布林治疗使OS获益Abstract 10503 -Trabectedin VS Dacarbazine与达卡巴嗪相比较，晚期患者接受曲贝替定治疗使PFS获益对于晚期脂肪肉瘤和平滑肌肉瘤患者曲贝替定是一种重要的治疗方法,
展开阅读全文